Analyst Price Targets — MGX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 21, 2024 6:16 am | Mitchell Kapoor | H.C. Wainwright | $7.00 | $3.30 | TheFly | Metagenomi price target lowered to $7 from $10 at H.C. Wainwright |
| March 28, 2024 7:49 am | Maury Raycrof | Jefferies | $22.00 | $11.09 | StreetInsider | Metagenomi Inc (MGX) PT Lowered to $22 at Jefferies |
Latest News for MGX
EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced two additions to its executive leadership team: Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer.
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK,
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D.
Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.68 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MGX.
U.S. House Trading
No House trades found for MGX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.